KRAS and cancer: Neither the frequently reported for other cancers [30, 31], the KRAS-TP53 co-mutation with dismal prognostic role, nor the other combinations, including the APC-KRAS-TP53 triple co-mutation, showed associations with survival of patients in the present study.